XPORT-EC-042

XPORT aims to evaluate the benefit of selinexor in patients with no TP53 alteration advanced or recurrent Endometrial Cancer. Patients will receive either oral selinexor or placebo as maintenance therapy following chemotherapy, until disease progression.

XPORT-EC-0422026-03-12T21:46:40+11:00

PEACE | ACTRN12621001031853

PEACE aims to determine the feasibility of collecting information from women, and their careers, with advanced gynaecological cancer about their experiences, satisfaction with care and symptom management towards end of life. Information collected focuses on how both patients and [...]

PEACE | ACTRN126210010318532026-03-12T21:46:33+11:00
Go to Top